Are you interested in meeting a unique community of life scientists, industries representatives and Neuroinflammation’s experts?
Do you want to learn more about your customers’ current needs and expectations?
Are you eager to gain visibility and show your products?
Don’t miss out on a good opportunity, and have a look at the sponsorship opportunities in our brochure here below.
Download the Sponsorship brochure here!
The 8th edition is supported by:
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Their purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. They do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. For more information visit novonordisk.com.
Ventus Therapeutics is a clinical-stage biopharmaceutical company deploying deep protein science expertise to develop novel small molecule therapeutics for immunology, inflammation, and neurology disorders. The company screened its first target in 2020, selected three development candidates in 2022, advanced its two wholly-owned product candidates into the clinic in 2023, and completed Phase 1 trials for both programs in 2024: VENT-03, a potent, selective, oral cGAS inhibitor, and VENT-02, a potent, brain-penetrant, oral NLRP3 inhibitor. Ventus has out-licensed VENT-01, a peripherally-restricted NLRP3 inhibitor to Novo Nordisk A/S.